Key Performance Indicators
Parmax Pharma is currently trading at Rs 76.58 on the BSE under ticker PARMAXPHAR, carrying a market capitalisation of Rs 28.65 crore. A price-to-earnings ratio is not reported for the current period, reflecting the company's current earnings profile. The six-month price return is +121.93%. The most recently reported quarterly net profit was a loss of Rs 0.58 crore, representing a year-on-year change of -38.10%. Quarterly sales stand at Rs 3.31 crore, with a year-on-year change of -31.47%. The return on capital employed (ROCE) is -82.96%. The all-time high price is Rs 81.90, above the current market price.
Highlights
Parmax Pharma has delivered a six-month price return of 121.93%, placing it among the notable performers on the BSE over the measured period. The all-time high of Rs 81.90 is above the current price of Rs 76.58, indicating the stock has corrected from its historical peak by approximately 6.5%. The market capitalisation of Rs 28.65 crore at this price level reflects the cumulative re-rating the market has applied to the company's equity.
A price-to-earnings ratio is not currently calculable, as the company's most recent reported quarter shows a net loss rather than a profit — a common feature of early-stage or transitional businesses that have been re-rated on expected future earnings rather than current profitability. India's healthcare sector expansion, rising insurance penetration, and government health mission investment provide structural demand growth for pharmaceutical and medical companies.
Business Overview
Parmax Pharma is a pharmaceutical company manufacturing or distributing generic drug formulations for the domestic Indian market. Small pharmaceutical companies at this scale typically produce a range of tablets, capsules, liquids, and ointments in basic therapeutic categories — analgesics, antibiotics, antacids — sold through pharmaceutical distributors to retail pharmacies and medical practitioners. The ROCE of -82.96% indicates the company is currently consuming capital at a significant rate relative to the business returns being generated.
The quarterly net loss of Rs 0.58 crore against quarterly sales of Rs 3.31 crore (with a year-on-year sales decline of -31.47%) reflects a business facing both revenue contraction and profitability challenges simultaneously. The six-month return of 121.93% from a market cap of just Rs 28.65 crore demonstrates that even small-scale re-rating events can produce very large percentage returns at this market size. The all-time high of Rs 81.90 is above the current Rs 76.58, indicating the stock has not yet exceeded its historical peak.
Financial Analysis
The financial profile of Parmax Pharma requires careful contextualisation. The six-month return of 121.93% has generated a market capitalisation of Rs 28.65 crore which must be assessed against the current operational scale: quarterly revenue of Rs 3.31 crore and quarterly net loss of Rs 0.58 crore. Without a positive P/E, the stock is valued on anticipated future earnings — a framework that requires visibility on the path to profitability and the timeline for achieving it.
The return on capital employed of -82.96% is negative, indicating the business is currently consuming capital rather than generating returns on it — a position that requires monitoring to assess whether the path to positive ROCE is visible through improving revenue and margin trends. The quarterly revenue decline of -31.47% year-on-year is a near-term concern that investors should investigate through the company's quarterly results commentary.
At Rs 28.65 crore market capitalisation, Parmax Pharma has micro-cap status. Investors should ensure they access and analyse the company's most recent quarterly results, annual report, and any corporate announcements on BSE before committing capital based solely on observed price performance.
Investor Highlights
The investment case for Parmax Pharma at the current price is determined by the gap between the current market capitalisation of Rs 28.65 crore and the company's intrinsic business value — a calculation that depends on assumptions about future revenue growth, margin improvement, and competitive positioning. The six-month return of 121.93% identifies this as a stock that the market has chosen to dramatically revalue upward, with the analytical question being whether the current valuation level is justified by the fundamental business trajectory.
With the current price of Rs 76.58 approximately 6.5% below the all-time high of Rs 81.90, the stock has experienced a correction from its historical peak. The key assessment is whether this correction represents a value opportunity — if the fundamental business case remains intact — or an ongoing normalisation following a period of speculative overextension.
The current quarterly loss position means the investment thesis is entirely forward-looking — dependent on a demonstrated path to profitability through revenue scale-up, margin improvement, or both. Investors should access the company's management commentary and business plan disclosures on BSE to assess the credibility and timeline of the profitability roadmap.
Frequently Asked Questions
Q: What does Parmax Pharma do and what sector does it operate in?
A: Parmax Pharma operates in the healthcare sector, listed on the BSE under the ticker PARMAXPHAR. The company's specific products, services, revenue model, and customer base are documented in its annual report and exchange filings available through the BSE corporate filing portal at bseindia.com.
Q: What does the six-month return of 121.93% reflect for Parmax Pharma?
A: The six-month return of 121.93% reflects significant positive market re-rating of the company's equity from its price six months prior. This re-rating may be driven by company-specific developments — new contracts, business expansion, or improved financial performance — or by broader sector-level positive sentiment. Investors should verify the specific triggers through the company's BSE exchange disclosures and quarterly results.
Q: How should investors value Parmax Pharma without a positive P/E ratio?
A: When a company reports a net loss, conventional P/E-based valuation is not directly applicable. Investors typically use price-to-sales, price-to-book, or discounted cash flow analysis — all of which require assumptions about when profitability will be achieved and at what margin level. The company's management commentary on the profitability path is a key input for this assessment.
Q: What is Parmax Pharma's current market capitalisation and all-time high?
A: Parmax Pharma has a market capitalisation of Rs 28.65 crore at the current price of Rs 76.58. The all-time high is Rs 81.90, which is above the current price, indicating the stock has corrected from its historical peak.
Q: Where can investors find Parmax Pharma's official financial data and corporate disclosures?
A: All of Parmax Pharma's financial disclosures — quarterly results, annual reports, shareholding patterns, board announcements, and corporate actions — are filed with the BSE and are freely accessible at bseindia.com through the company's filing page. SEBI's listing obligations mandate timely disclosure of all material developments. These filings are the primary source of verified financial and operational information for investment assessment.